Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort

Kyle Melin, Jee Young Moon, Qibin Qi, Dagmar F. Hernandez-Suarez, Jorge Duconge, Simin Hua, Sara Gonzalez Rodriguez de Castro, Donglin Zeng, Robert C. Kaplan

Research output: Contribution to journalArticle

Abstract

Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10% of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3% will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds. Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Results: MAFs for six out of nine variants differed between Caribbean and Mainland subpopulations (p < 0.05). Compared with European reference group, MAFs of ABCB1, CES1 and PON1 were higher in Hispanic Community Health Study/Study of Latinos, whereas B4GALT2 and CYP2C19∗2 and ∗17 were lower. Conclusion: Significant differences in the prevalence of most pharmacogenomic variants related to clopidogrel response provide a foundation to better inform ongoing and future clinical studies of clopidogrel pharmacogenetics in the US Hispanic/Latino populations.

Original languageEnglish (US)
Pages (from-to)75-83
Number of pages9
JournalPharmacogenomics
Volume20
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

clopidogrel
Hispanic Americans
Cohort Studies
Health
Therapeutics
Purinergic P2Y Receptor Antagonists
Pharmacogenomic Variants
Pharmacogenetics
Acute Coronary Syndrome
Gene Frequency

Keywords

  • ABCB1
  • B4GALT2
  • CES1
  • clopidogrel
  • CYP2C19
  • Hispanic
  • Latino
  • P2RY12
  • pharmacogenes
  • PON1

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. / Melin, Kyle; Moon, Jee Young; Qi, Qibin; Hernandez-Suarez, Dagmar F.; Duconge, Jorge; Hua, Simin; Rodriguez de Castro, Sara Gonzalez; Zeng, Donglin; Kaplan, Robert C.

In: Pharmacogenomics, Vol. 20, No. 2, 01.01.2019, p. 75-83.

Research output: Contribution to journalArticle

@article{2523c2d8599f461897091d918ff1b632,
title = "Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort",
abstract = "Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10{\%} of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3{\%} will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds. Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Results: MAFs for six out of nine variants differed between Caribbean and Mainland subpopulations (p < 0.05). Compared with European reference group, MAFs of ABCB1, CES1 and PON1 were higher in Hispanic Community Health Study/Study of Latinos, whereas B4GALT2 and CYP2C19∗2 and ∗17 were lower. Conclusion: Significant differences in the prevalence of most pharmacogenomic variants related to clopidogrel response provide a foundation to better inform ongoing and future clinical studies of clopidogrel pharmacogenetics in the US Hispanic/Latino populations.",
keywords = "ABCB1, B4GALT2, CES1, clopidogrel, CYP2C19, Hispanic, Latino, P2RY12, pharmacogenes, PON1",
author = "Kyle Melin and Moon, {Jee Young} and Qibin Qi and Hernandez-Suarez, {Dagmar F.} and Jorge Duconge and Simin Hua and {Rodriguez de Castro}, {Sara Gonzalez} and Donglin Zeng and Kaplan, {Robert C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/pgs-2018-0148",
language = "English (US)",
volume = "20",
pages = "75--83",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort

AU - Melin, Kyle

AU - Moon, Jee Young

AU - Qi, Qibin

AU - Hernandez-Suarez, Dagmar F.

AU - Duconge, Jorge

AU - Hua, Simin

AU - Rodriguez de Castro, Sara Gonzalez

AU - Zeng, Donglin

AU - Kaplan, Robert C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10% of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3% will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds. Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Results: MAFs for six out of nine variants differed between Caribbean and Mainland subpopulations (p < 0.05). Compared with European reference group, MAFs of ABCB1, CES1 and PON1 were higher in Hispanic Community Health Study/Study of Latinos, whereas B4GALT2 and CYP2C19∗2 and ∗17 were lower. Conclusion: Significant differences in the prevalence of most pharmacogenomic variants related to clopidogrel response provide a foundation to better inform ongoing and future clinical studies of clopidogrel pharmacogenetics in the US Hispanic/Latino populations.

AB - Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10% of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3% will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds. Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Results: MAFs for six out of nine variants differed between Caribbean and Mainland subpopulations (p < 0.05). Compared with European reference group, MAFs of ABCB1, CES1 and PON1 were higher in Hispanic Community Health Study/Study of Latinos, whereas B4GALT2 and CYP2C19∗2 and ∗17 were lower. Conclusion: Significant differences in the prevalence of most pharmacogenomic variants related to clopidogrel response provide a foundation to better inform ongoing and future clinical studies of clopidogrel pharmacogenetics in the US Hispanic/Latino populations.

KW - ABCB1

KW - B4GALT2

KW - CES1

KW - clopidogrel

KW - CYP2C19

KW - Hispanic

KW - Latino

KW - P2RY12

KW - pharmacogenes

KW - PON1

UR - http://www.scopus.com/inward/record.url?scp=85059878168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059878168&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0148

DO - 10.2217/pgs-2018-0148

M3 - Article

VL - 20

SP - 75

EP - 83

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 2

ER -